Form 4: Kiniksa Pharmaceuticals CEO Sanj K Patel Reports Stock Transactions
SEC Form 4 Filing
Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals, reported the vesting of restricted share units and associated tax withholding.
Summary
- On April 1, 2024, Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals, reported transactions involving Class A Common Shares.
- These transactions included the vesting of 6,482 Restricted Share Units (RSUs) and the withholding of 1,903 shares to cover tax obligations.
- Following these transactions, Patel directly owns 57,095 Class A Common Shares and indirectly owns 109,795 shares held by The Marina 2016 Irrevocable Trust.
- He also directly owns 19,443 Restricted Share Units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard compensation practices, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.
Key Dates
| Date | Description |
|---|---|
| June 23, 2016 | Date of trust agreement for The Marina 2016 Irrevocable Trust |
| April 1, 2023 | Grant date of the Restricted Share Units (RSUs) that vest over four years. |
| April 1, 2024 | Date of transaction: vesting of RSUs and tax withholding. |
| April 3, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.